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Effect of Periodontal Treatment on HbA1c 
among Patients with Prediabetes
T. Kocher1*, B. Holtfreter1* , A. Petersmann2, P. Eickholz3 , T. Hoffmann4,  
D. Kaner5,6, T.S. Kim7, J. Meyle8, U. Schlagenhauf9, S. Doering10, M. Gravemeier11, 
K. Prior11, W. Rathmann12, I. Harks11, B. Ehmke11†, and R. Koch13†
Abstract
Evidence is limited regarding whether periodontal treatment improves hemoglobin A1c (HbA1c) among people with prediabetes and 
periodontal disease, and it is unknown whether improvement of metabolic status persists >3 mo. In an exploratory post hoc analysis 
of the multicenter randomized controlled trial “Antibiotika und Parodontitis” (Antibiotics and Periodontitis)—a prospective, stratified, 
double-blind study—we assessed whether nonsurgical periodontal treatment with or without an adjunctive systemic antibiotic treatment 
affects HbA1c and high-sensitivity C-reactive protein (hsCRP) levels among periodontitis patients with normal HbA1c (≤5.7%, n = 218), 
prediabetes (5.7% < HbA1c < 6.5%, n = 101), or unknown diabetes (HbA1c ≥ 6.5%, n = 8) over a period of 27.5 mo. Nonsurgical 
periodontal treatment reduced mean pocket probing depth by >1 mm in both groups. In the normal HbA1c group, HbA1c values 
remained unchanged at 5.0% (95% CI, 4.9% to 6.1%) during the observation period. Among periodontitis patients with prediabetes, 
HbA1c decreased from 5.9% (95% CI, 5.9% to 6.0%) to 5.4% (95% CI, 5.3% to 5.5%) at 15.5 mo and increased to 5.6% (95% CI, 5.4% 
to 5.7%) after 27.5 mo. At 27.5 mo, 46% of periodontitis patients with prediabetes had normal HbA1c levels, whereas 47.9% remained 
unchanged and 6.3% progressed to diabetes. Median hsCRP values were reduced in the normal HbA1c and prediabetes groups from 
1.2 and 1.4 mg/L to 0.7 and 0.7 mg/L, respectively. Nonsurgical periodontal treatment may improve blood glucose values among 
periodontitis patients with prediabetes (ClinicalTrials.gov NCT00707369).
Keywords: clinical trial, subgroup analysis, periodontitis, hemoglobin A1c, prediabetic state, C-reactive protein
172 Journal of Dental Research 98(2)
Introduction
The prevalence of diabetes continues to rise worldwide. 
Between 2015 and 2040, the global prevalence of type 2 diabe-
tes mellitus (T2DM) is predicted to increase from 8.8% to 
10.4% (Ogurtsova et al. 2017). Between 9.3% and 55% of per-
sons with prediabetes annually converted to T2DM within 3 y 
(Kerrison et al. 2017). Because the majority of people with 
prediabetes might progress to diabetes during the lifetime, the 
burden of T2DM could be reduced if prediabetes treatment 
covered a large part of the population at risk (Tabak et al. 
2012). Prediabetes is related to increased mortality, morbidity, 
and health care costs, thus constituting an important public 
health problem. Alleviating the progression of prediabetes to 
T2DM is a reasonable way to reduce the diabetes epidemic and 
lessen health care costs. Indeed, lifestyle modifications or drug 
interventions among persons with prediabetes reduced the 
incidence of diabetes by 25% to 72% during 2-, 4-, and 6-y 
intervention periods (Eyre et al. 2004), and short-term glyce-
mic control regressed to normoglycemia for many subjects 
with lifestyle modification. Although glycemic control wors-
ened again over 3 to 5 y, it was still superior versus baseline 
results and control groups (Kerrison et al. 2017).
Elevated serum levels of C-reactive protein (CRP) were 
observed among prediabetic subjects over normoglycemic 
subjects, whereas no further CRP increase was observed 
between prediabetes and manifest diabetes, which may reflect 
early activation of the immune system (Grossmann et al. 2015). 
Higher serum levels of inflammatory markers were associated 
with the development of T2DM (Bo et al. 2017; Koloverou 
et al. 2017). Adjunctive treatment with anti-inflammatory drugs 
among subjects with prediabetes (Faghihimani et al. 2012) or 
T2DM (Larsen et al. 2007; Goldfine et al. 2013) reduced 
hemoglobin A1c (HbA1c) and inflammatory markers.
Periodontitis is a highly prevalent, bacterially induced 
inflammatory oral disease that results in pocket formation and 
breakdown of alveolar bone. Periodontitis is linked with a 
higher risk of HbA1c progression and diabetes through sys-
temic low-grade inflammation (Demmer et al. 2008). Through 
an ulcerated periodontal pocket epithelium, oral pathogens or 
their metabolic products can enter the bloodstream during 
toothbrushing or chewing (Lockhart et al. 2008), in turn pro-
voking an immune response and causing low-grade systemic 
inflammation. Another pathway may be leakage of proinflam-
matory cytokines into the main bloodstream, which might also 
affect the metabolic state (Loos et al. 2000).
Periodontal treatment reduces serum levels of inflamma-
tory markers. A meta-analysis of clinical trials that investigated 
the effect of periodontal treatment on HbA1c levels found an 
HbA1c decrease of 0.29% at 3 mo after periodontal treatment 
(Simpson et al. 2015). All these studies, however, were per-
formed on patients with long-standing diabetes, and periodon-
tal treatment was only an adjunct to routine medical antidiabetic 
treatment. To date, studies evaluating the effects of periodontal 
scaling on metabolic control among persons with prediabetes 
reported inconsistent results (Faghihimani et al. 2013; Javed 
et al. 2014; Alshehri and Javed 2015).
The use of antibiotics as an adjunct to subgingival scaling 
reduced more periodontal pockets than did scaling alone 
(Harks et al. 2015). The consumption of amoxicillin signifi-
cantly decreased positive blood culture results after tooth-
brushing (Lockhart et al. 2008), whereas more recent literature 
is equivocal regarding whether antibiotics as an adjunct to 
scaling has an additional impact on inflammatory markers 
(Demmer et al. 2013; Giannopoulou et al. 2016). Adjunctive 
intake of antibiotics did not improve hyperglycemia among 
uncontrolled patients with T2DM over scaling alone (Simpson 
et al. 2015). Furthermore, for people with prediabetes, 7-d 
amoxicillin intake did not affect insulin sensitivity or systemic 
low-grade inflammation (Reijnders et al. 2016).
In an exploratory subgroup analysis of the multicenter (8 
university hospital centers) randomized controlled trial 
“Antibiotika und Parodontitis” (Antibiotics and Periodontitis; 
ABPARO), we examined whether nonsurgical periodontal 
treatment with or without an adjunctive systemic antibiotic 
treatment 1) affects HbA1c levels among periodontitis patients 
with normal HbA1c, prediabetes, or unknown diabetes and 2) 
decreases the proportion of periodontitis patients with predia-
betes over a period of 27.5 mo.
Research and Design Methods
Study Design
This is an exploratory analysis of data from the prospective 
ABPARO trial with a parallel-group design (Current Controlled 
Trials ISRCTN64254080; ClinicalTrials.gov NCT00707369). 
The stratified double-blind ABPARO trial assessed the effect 
of an adjunctive antibiotic treatment in addition to scaling on 
the progression of periodontal disease (Harks et al. 2014). The 
protocol, details of the trial and procedures, and a description 
of the periodontal treatment are available in the Appendix.
Study Population
Out of 345 patients from the per-protocol collective of the 
main study, 17 were excluded because of known diabetes and 
1 because of missing baseline HbA1c levels, leaving 327 
patients. In the multivariable analysis, 1 further patient was 
excluded because of missing data (n = 326). Both treatment 
groups were pooled for the current analysis since, in terms of 
treatment allocation, there were no statistically significant dif-
ferences either in HbA1c levels (interaction between treatment 
and visit: B = −0.054 [95% CI, −0.210 to 0.102] for 15.5 mo 
and B = −0.125 [95% CI, −0.291 to 0.041] for 27.5 mo; covariate-
adjusted mixed model; per-protocol sample; Appendix Table 
5) or in high-sensitivity CRP (hsCRP) levels (log-transformed; 
interaction between treatment and visit: B = −0.0001 [95% CI, 
−0.202 to 0.202] for 15.5 mo and B = 0.006 [95% CI, −0.200 
to 0.212] for 27.5 mo; covariate-adjusted mixed model; per-
protocol sample; Appendix Table 6). On the basis of their base-
line HbA1c levels, patients were stratified into 218 subjects 
with normal HbA1c, 101 prediabetes subjects, and 8 subjects 
with previously unknown diabetes.
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Statistical Analyses
Statistical analyses were performed with SAS software (ver-
sion 9.4; SAS Institute). P values and confidence intervals 
were intended to be exploratory, not confirmatory. Therefore, 
neither global nor local significance levels were determined, 
and no adjustment for multiplicity was applied. Exploratory P 
values ≤0.05 were considered statistically relevant.
Categorical variables were shown as frequencies (percent-
ages). Normally distributed variables were presented as mean ± SD; nonnormally distributed variables were described by 
median (25% and 75% quantiles). The change of HbA1c group 
affiliation between baseline and follow-up visits (15.5 and 27.5 
mo) was described with contingency tables and analyzed with 
marginal homogeneity tests (Stuart 1955). Spearman correla-
tion coefficients (r
Sp
) were calculated.
Multivariable analyses were performed to estimate covariate-
adjusted effects of baseline HbA1c status and visit on HbA1c 
levels at follow-up visits. To account for missing values 
(treated as missing at random) and dependencies among 
repeated measurements, linear mixed models were fitted 
(Verbeke and Molenberghs 2000). Independent variables 
included HbA1c group (baseline), visit, and the interaction 
between HbA1c group (baseline) and visit, as well as baseline 
levels of treatment, age, sex, body mass index (BMI), and 
smoking status. Repeated measurements of HbA1c were mod-
eled with heterogeneous residual covariance variance (unstruc-
tured) with the patient as the subject. Such a variance structure 
takes into account that within-group variance of baseline 
HbA1c levels is artificially restricted due to categorization. 
This means we allow the residual variance to be different for 
each visit, as well as the covariance between the different mea-
surements. In our model, the estimated residual variances 
increased slightly from baseline to 15.5 mo and 27.5 mo. 
Results were reported as linear regression coefficients (B) and 
corresponding 95% CIs. Furthermore, least square means of 
HbA1c (percentage; with 95% CIs and P values) were estimated 
for linear combinations of coefficients adjusted for covariates.
Results
Study Participants
Periodontitis patients with prediabetes (54.0 ± 9.2 y) were 2.3 y 
older than those with normal HbA1c levels (51.7 ± 10.8 y) and 
5 y younger than periodontitis patients with unknown diabetes 
(59.0 ± 8.1 y; Table 1). Furthermore, they were slightly more 
obese or overweight than their counterparts with normal 
HbA1c.
Crude Effects of Periodontal Treatment on 
HbA1c Levels and Conversion of HbA1c Status
In all 3 groups, periodontal treatment noticeably reduced mean 
levels of pocket probing depth (PPD; Table 2). Median hsCRP 
values decreased in the normal, prediabetes, and diabetes 
groups from 1.2, 1.4, and 1.6 to 0.7, 0.7, and 0.9 mg/L, respec-
tively (group-specific changes in HbA1c levels described in 
detail later).
For periodontitis patients with normal HbA1c levels, mean 
HbA1c values remained unchanged at 5.0% (15.5-mo visit: 
95% CI, 4.9% to 6.1%; 27.5-mo visit: 95% CI, 4.9% to 6.1%) 
during the observation period (Table 2, Figure A). However, 
14.5% progressed to prediabetes and 1.4% to diabetes after 
27.5 mo, while 84.1% remained at normal HbA1c levels (Table 
3). This pattern was also obvious for the individual courses 
(Figure B).
Table 1. Baseline Patient Characteristics According to Baseline HbA1c Status.
Normal HbA1ca (n = 218) Prediabetesb (n = 101) Diabetesc (n = 8)
Age, y 51.7 ± 10.8 54.0 ± 9.2 59 ± 8.1
Sex  
 Male 104 (48) 53 (52) 4 (50)
 Female 114 (52) 48 (48) 4 (50)
Treatment  
 Placebo 113 (52) 50 (50) 2 (25)
 Antibiotics 105 (48) 51 (50) 6 (75)
Body mass index, kg/m2 25.3 ± 4.4 26.1 ± 4.1 28.7 ± 6.2
 <25 114 (52) 46 (45) 2 (25)
 ≥25 to <30 78 (36) 37 (37) 4 (50)
 ≥30 26 (12) 18 (18) 2 (25)
Current smoking status  
 Nonsmoker 163 (75) 69 (68) 6 (75)
 Smoker 55 (25) 32 (32) 2 (25)
Number of teeth 26 (23; 28) 25 (23; 27) 23.5 (22; 26)
Data are presented as mean ± SD, median (25% quantile; 75% quantile), or n (%).
HbA1c, hemoglobin A1c.
aHbA1c ≤5.7% or ≤38.8 mmol/mol.
b5.7% < HbA1c < 6.5% or 38.8 mmol/mol < HbA1c < 47.54 mmol/mol.
cHbA1c ≥ 6.5% or ≥47.54 mmol/mol.
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Table 2. Periodontal and Laboratory Measurements at Baseline, 15.5-mo Examinations, 27.5-mo Examinations, and Respective Changes from Baseline.
Visit Observed Value Change from Baseline
Normal HbA1ca
Mean PPD, mm  
 Baseline 3.4 ± 0.7  
 15.5 mo 2.5 ± 0.6 –0.9 ± 0.6
 27.5 mo 2.5 ± 0.6 –0.9 ± 0.7
Bleeding on probing, %  
 Baseline 33.3 (21.8; 47.2)  
 15.5 mo 12.5 (6.5; 22.2) –19.4 (–31.5; –5.4)
 27.5 mo 11.8 (6.3; 23.9) –18.9 (–33.3; –5.9)
HbA1c, %  
 Baseline 5.0 ± 0.6  
 15.5 mo 5.0 ± 0.6 0.0 ± 0.7
 27.5 mo 5.0 ± 0.7 0.0 ± 0.8
HbA1c, mmol/mol  
 Baseline 31.1 ± 6.3  
 15.5 mo 31.0 ± 6.8 –0.1 ± 7.9
 27.5 mo 31.3 ± 7.9 0.1 ± 8.6
hsCRP, mg/L  
 Baseline 1.2 (0.5; 2.8)  
 15.5 mo 0.7 (0.4; 1.4) –0.3 (–1.4; 0.0)
 27.5 mo 0.7 (0.4; 1.3) –0.5 (–1.5; 0.0)
Prediabetesb
Mean PPD, mm  
 Baseline 3.7 ± 0.7  
 15.5 mo 2.7 ± 0.7 –1.0 ± 0.7
 27.5 mo 2.5 ± 0.7 –1.1 ± 0.8
Bleeding on probing, %  
 Baseline 33.3 (25.0; 50.0)  
 15.5 mo 12.5 (6.2; 21.7) –19.0 (–31.0; –6.3)
 27.5 mo 13.2 (5.0; 22.7) –19.6 (–30.4; –9.0)
HbA1c, %  
 Baseline 5.9 ± 0.2  
 15.5 mo 5.4 ± 0.5 –0.5 ± 0.5
 27.5 mo 5.6 ± 0.6 –0.4 ± 0.6
HbA1c, mmol/mol  
 Baseline 41.2 ± 2.3  
 15.5 mo 35.3 ± 5.7 –5.9 ± 5.5
 27.5 mo 37.4 ± 6.9 –3.9 ± 6.6
hsCRP, mg/L  
 Baseline 1.5 (0.8; 3.1)  
 15.5 mo 0.8 (0.5; 1.5) –0.4 (–1.7; 0.0)
 27.5 mo 0.7 (0.4; 1.3) –0.6 (–2.0; –0.2)
Diabetesc
Mean PPD, mm  
 Baseline 3.8 ± 0.6  
 15.5 mo 2.5 ± 0.3 –1.3 ± 0.7
 27.5 mo 2.4 ± 0.2 –1.4 ± 0.7
Bleeding on probing, %  
 Baseline 36.2 (22.9; 53.6)  
 15.5 mo 11.2 (6.5; 14.9) –22.1 (–44.9; –10.8)
 27.5 mo 13.9 (3.6; 20.8) –28.5 (–51.7; –2.7)
HbA1c, %  
 Baseline 6.6 ± 0.1  
 15.5 mo 5.7 ± 0.9 –0.9 ± 0.8
 27.5 mo 5.7 ± 0.7 –0.9 ± 0.6
HbA1c, mmol/mol  
 Baseline 49.0 ± 1.5  
 15.5 mo 38.9 ± 9.7 –10.1 ± 9.2
 27.5 mo 38.8 ± 7.6 –10.2 ± 7.0
hsCRP, mg/L  
 Baseline 1.6 (1.1; 5.6)  
 15.5 mo 1.2 (0.7; 1.5) –0.5 (–4.1; –0.2)
 27.5 mo 0.9 (0.5; 1.6) –0.7 (–4.7; –0.2)
Data are presented as mean ± SD or median (25% quantile; 75% quantile).
HbA1c, hemoglobin A1c; hsCRP, high-sensitivity C-reactive protein; PPD, pocket probing depth.
aHbA1c ≤5.7% or ≤38.8 mmol/mol.
b5.7% < HbA1c < 6.5% or 38.8 mmol/mol < HbA1c < 47.54 mmol/mol.
cHbA1c ≥ 6.5% or ≥47.54 mmol/mol.
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In the prediabetes group, mean 
HbA1c decreased from 5.9% (95% 
CI, 5.9% to 6.0%) to 5.4% (95% CI, 
5.3% to 5.5%) after 15.5 mo and 
rebounded to 5.6% (95% CI, 5.4% 
to 5.7%) after 27.5 mo (Table 2, 
Figure A). Furthermore, change in 
mean PPD during the 27.5-mo fol-
low-up period correlated weakly 
but positively with change in 
HbA1c levels among patients with 
prediabetes (r
Sp
 = 0.17, excluding 
subjects with hsCRP >10 mg/L at 
any visit), but an association cannot 
be concluded. In terms of visit-
dependent conversions of the 
HbA1c status (Table 3), 30% 
remained in the prediabetes state 
after 15.5 mo, whereas 69% had 
normal HbA1c levels and only 1 
patient progressed to diabetes. After 
27.5 mo, the proportion of subjects 
with normal HbA1c levels 
decreased to 45.8%, while 47.9% 
had prediabetes and 6.3% had dia-
betes. Increasing variances of 
HbA1c levels within visits were 
also evident from individual trajec-
tory plots (Figure B), confirming 
that a high proportion of periodon-
titis patients with prediabetes con-
verted to the normal HbA1c group.
In the unknown diabetes group, 
mean HbA1c dropped from 6.6% 
(95% CI, 6.5% to 6.8%) to 5.7% 
(95% CI, 5.0% to 6.5%) after 15.5 
mo and persisted at 5.7% (95% CI, 
5.1% to 6.3%) until the end of the 
observation period (Table 2, Figure 
A). Of 8 subjects with unknown 
diabetes at baseline, only 1 patient still had an HbA1c level in 
the diabetic range after 27.5 mo; the remaining 7 subjects 
changed to prediabetes (n = 4) or normal HbA1c (n = 3) after 
27.5 mo (Table 3). Individual courses (Figure B) revealed that 
for patients converting to a better HbA1c status after 27.5 mo 
(n = 7), HbA1c levels were consistently reduced over 27.5 mo.
Adjusted Effects of Periodontal Treatment on 
HbA1c Levels
With the per-protocol sample, covariate-adjusted linear mixed 
models (Appendix Tables 1 and 2) revealed that HbA1c levels 
did not change statistically in the group with normal HbA1c 
but decreased noticeably between baseline and both follow-up 
visits in the prediabetic and diabetic groups (see Figure C for 
predicted margins of HbA1c). In the prediabetic and unknown 
diabetes groups, estimated mean HbA1c levels changed by 
−0.352% (95% CI, −0.472% to −0.231%; P < 0.001) and 
−0.938% (95% CI, −1.355% to −0.520%; P < 0.001), respec-
tively, over 27.5 mo (Figure C, Appendix Table 2). Additionally, 
increasing body mass index was associated with increasing 
mean HbA1c levels (P = 0.07), whereas a noticeable influence 
of age, treatment, and smoking status on HbA1c could not be 
detected (all P > 0.05; Appendix Table 1).
With the intention-to-treat  sample, results were consistent 
such that HbA1c levels decreased noticeably between baseline 
and both follow-up visits in the prediabetic and diabetic groups 
(Appendix Tables 3 and 4).
Figure. Graphical representation of observed values and model predicted margins of hemoglobin 
A1c (HbA1c). (A) Boxplot showing HbA1c levels over visits stratified by baseline HbA1c status. 
Values are presented as median, 25% and 75% quantiles, whiskers corresponding to minimum and 
maximum values within the interval [25% quantile - 1.5 × interquartile range, 75% quantile + 1.5 × 
interquartile range], and outliers (× denotes the mean). (B) Individual courses of HbA1c levels over 
visits stratified by baseline HbA1c status (each line denotes 1 patient). (C) Predicted margins (least 
square means with 95% CIs) of HbA1c from the linear mixed model grouped by baseline HbA1c 
status and visit. Covariate-adjusted P values are presented for comparisons with baseline Hba1c levels 
within groups defined by baseline HbA1c status. The underlying linear mixed model and estimated 
average HbA1c levels for pairwise group comparisons are presented in Appendix Tables 1 and 2.
176 Journal of Dental Research 98(2)
Discussion
Among persons with prediabetes, nonsurgical periodontal 
treatment halved their number to 48% after 27.5 mo as com-
pared with baseline, and mean HbA1c levels were reduced 
from 5.9% to 5.6% irrespective of adjunctive antibiotic ther-
apy. In parallel to HbA1c improvements, reductions in local 
periodontal inflammation, pocket depths, and low-grade sys-
temic inflammation were observed. In covariate-adjusted mod-
els, nonsurgical periodontal treatment reduced HbA1c by 
0.352% over 27.5 mo. Among periodontitis patients with nor-
mal HbA1c, mean HbA1c levels did not change, but 14.5% of 
subjects progressed to prediabetes and 1.4% to diabetes, 
although low-grade systemic inflammation was reduced over 
the complete time span.
Study results for periodontitis patients with prediabetes are 
in agreement with previously published short-term trials (Javed 
et al. 2014; Lalla et al. 2015) reporting that HbA1c levels 
decreased significantly after periodontal treatment among peo-
ple with prediabetes (Javed et al. 2014) and unknown diabetes 
(Lalla et al. 2015) after 3 and 6 mo, respectively. An HbA1c 
reduction of 0.3% to 0.5% is comparable to that achieved 
among periodontally treated patients with pharmacologically 
managed diabetes (Simpson et al. 2015). Taken together, these 
results support the idea that periodontitis patients who are 
unaware of their metabolic status might benefit from periodon-
tal treatment.
A mean HbA1c decrease of 0.3% to 0.4% is comparable to 
reductions reached with lifestyle or drug interventions among 
people with prediabetes (Chiasson 2007). In the Diabetes 
Prevention Program Outcomes Study, the risk of developing 
T2DM was 56% lower among subjects who returned to normal 
glycemic control as compared with permanently prediabetic 
subjects (Perreault et al. 2012). In our study, the reduction of 
low-grade inflammation in the prediabetes group persisted over 
27.5 mo, whereas HbA1c levels rebounded from 15.5 to 27.5 
mo, as did the percentage of prediabetic subjects from 30% to 
47.9%. It is probable that periodontal treatment improved insu-
lin sensitivity via reduced systemic inflammation and thus 
delayed the progression from prediabetes to beta-cell dysfunc-
tion as it is observed in diabetes mellitus. Comparable results 
were observed in the Diabetes Prevention Program Outcomes 
Study, whose authors concluded that “prediabetes is a high-risk 
state for diabetes. . . . Reversion to normal glucose regulation, 
even if transient, is associated with a significantly reduced risk 
of future diabetes” (Perreault et al. 2012).
Overall, our results are consistent with findings from phar-
macologic studies of prediabetes patients demonstrating that—
irrespective of the drugs used—drug treatment only delayed 
diabetes onset rather than preventing it (Kanat et al. 2015). The 
authors argued that greater glycemic improvement was brought 
about by enhanced insulin sensitivity rather than improved 
beta-cell function.
In our study, hsCRP reduction over 27.5 mo ranged between 
−0.5 and −0.7 mg/L. A meta-analysis raised the question of 
whether a modest short-term CRP reduction of 0.4 mg/L after 
periodontal therapy would translate into any clinical benefit 
(Demmer et al. 2013). Regarding persons with prediabetes, our 
results suggest that even such a modest hsCRP reduction 
improves hyperglycemia to an extent comparable to that of 
daily adjunctive intake of anti-inflammatory drugs among dia-
betic subjects, besides established antidiabetic drugs (Goldfine 
et al. 2013) or metformin. Thus, one might deduce some clini-
cal benefit for periodontal treatment among periodontitis 
patients with prediabetes.
The Centers for Disease Control and Prevention (2014) 
reported that 37% of US adults aged ≥20 y had prediabetes 
from 2009 to 2012, and 45.9% had moderate to severe peri-
odontitis (Eke et al. 2015). In our patient population as well as 
others (Holm et al. 2016), about one-third of periodontally dis-
eased subjects had prediabetes. Given that approximately 30% 
to 40% of the population has moderate or severe periodontitis 
(Konig et al. 2010), periodontal treatment may influence pre-
diabetes in the general population. However, to affect HbA1c, 
periodontal treatment must be performed to high standards, 
and patients must be compliant with maintenance sessions to 
maintain healthy periodontal conditions.
In this study, 14.5% (n = 31) of periodontitis patients with 
normal baseline HbA1c levels progressed to prediabetes, and 
1.4% subjects (n = 3) progressed to diabetes after 27.5 mo, 
although mean PPD and hsCRP levels were on average reduced 
over the complete time span. This finding shows that despite 
Table 3. Change of HbA1c Status between Baseline and 15.5- or 27.5-mo Examinations.
HbA1c Status at 15.5 mo (n = 321)  
HbA1c Status at Baseline Baseline, n Normal Prediabetes Diabetes P Value
Normal 213 189 (88.7) 23 (10.8) 1 (0.5)  
Prediabetes 100 69 (69.0) 30 (30.0) 1 (1.0)  
Diabetes   8 2 (25.0) 5 (62.5) 1 (12.5) <0.001
 HbA1c Status at 27.5 mo (n = 318)  
Normal 214 180 (84.1) 31 (14.5) 3 (1.4)  
Prediabetes  96 44 (45.8) 46 (47.9) 6 (6.3)  
Diabetes   8 3 (37.5) 4 (50.0) 1 (12.5) 0.27
Results are reported as n (%; by row). P values are from marginal homogeneity tests (Stuart-Maxwell).
HbA1c, hemoglobin A1c.
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effective periodontal treatment, glycemic control worsened for 
1 in 8 patients with normal baseline HbA1c levels, irrespective 
of the follow-up periodontal status. This observation might be 
related to natural variation of HbA1c levels over time such that 
periodontitis patients with baseline HbA1c levels near the 5.7% 
threshold exhibit levels slightly above 5.7% at follow-up visits. 
However, for 3 patients, HbA1c levels were in the diabetic 
range (7% at maximum) after 27.5 mo (Figure B). Nevertheless, 
the majority (84.1%) remained in the normal group.
Some strengths and limitations of this study deserve consid-
eration. Strengths include the relatively high sample size, also 
within subgroups of normal HbA1c and prediabetes subjects. 
Among the limitations, this was a secondary analysis including 
patient data pooled over treatment allocation. This was justi-
fied by nonsignificant effects of treatment allocation on change 
in HbA1c levels (Appendix Table 5) and hsCRP levels 
(Appendix Table 6) between baseline and follow-up visits, as 
indicated by the interaction terms between treatment allocation 
and visit. The results for hsCRP were in agreement with a pre-
vious randomized clinical trial with comparable treatment 
groups that reported no differences between treatment arms 
with regard to rates of change in CRP levels (Lopez et al. 
2012). In this context, it should again be noted that randomiza-
tion across groups defined by baseline HbA1c status was 
absent in this study. This was handled by implementation of 
linear mixed models with an unstructured covariance structure 
and comprehensive adjustments for covariates. Furthermore, 
linear mixed models enabled handling of records with missing 
data. In addition, the per-protocol and intention-to-treat sam-
ples yielded consistent results with regard to direction and size 
of least square mean estimates such that HbA1c levels 
decreased by 0.35% and 0.95% between baseline and both 
follow-up visits in the prediabetic and diabetic groups with 
either sample, respectively. Second, the absence of robust 
physiologic measurements limits a mechanistic interpretation 
of our observations. Third, information on new antidiabetic 
medication during the trial period was recorded not directly but 
through the medication change comment field (see Appendix). 
Thus, we cannot exclude that information on new antidiabetic 
medication was incomplete. Nevertheless, these comment 
fields indicated no new antidiabetic medication during the trial 
period. Thus, we assume that HbA1c reductions were not 
related to changes in antidiabetic medication. Fourth, intake of 
anti-inflammatory medication during the trial period might 
have affected changes in systemic inflammation and, thus, 
HbA1c levels. However, at any visit, a maximum of 10, 6, and 
1 patients from the normal, prediabetes, and diabetes groups 
took acetylsalicylic acid, respectively (see Appendix). Thus, 
potential effects on changes in systemic inflammation and 
HbA1c levels may be negligible.
Last, decreasing HbA1c levels among persons with predia-
betes at baseline might have occurred due to regression to the 
mean instead of being related to the periodontal treatment 
itself. On the one hand, if regression to the mean was present, 
a greater decrease in HbA1c levels would be more often 
observed for prediabetes subjects with higher baseline HbA1c 
levels. However, as seen in time course plots (see Figure B, 
prediabetes group), changes in HbA1c measurements were not 
related to baseline HbA1c levels, which does not support the 
assumption that the decreasing HbA1c levels of prediabetes 
subjects were related to regression to the mean. On the other 
hand, correlation plots of changes in mean PPD and HbA1c 
levels between baseline and 27.5-mo examinations support the 
notion that changes in HbA1c levels might have been related to 
periodontal treatment. Indeed, most periodontitis patients 
showed improvements in mean PPD and HbA1c levels, and the 
Spearman correlation for periodontitis patients with prediabe-
tes was 0.17, indicating a weak but positive correlation. In 
addition, previous studies support the notion that the reduc-
tions seen in this study were probably due to periodontal treat-
ment rather than regression to the mean. In randomized clinical 
trials that evaluated effects of periodontal treatment on meta-
bolic control, periodontally untreated diabetes patients (con-
trols) showed unchanged HbA1c levels (Engebretson et al. 
2013; Zhang et al. 2013). Nevertheless, we cannot exclude the 
possibility that changes in HbA1c levels occurred due to 
regression to the mean, bias potentially introduced by the study 
design (i.e., no randomization across groups defined by base-
line HbA1c status), or other causes, thereby precluding any 
causal interpretation of the results. Thus, our secondary analy-
sis should rather be regarded as hypothesis generating. Only a 
study with a randomized double-blind design can determine 
whether observations seen in this study will hold true.
In summary, this exploratory subgroup analysis of the mul-
ticenter randomized controlled ABPARO trial—a prospective, 
stratified, double-blind study—suggests that nonsurgical peri-
odontal treatment might reduce systemic hyperglycemia 
among people with prediabetes. In parallel, local periodontal 
inflammation and low-grade systemic inflammation decreased 
over the follow-up period. If one-third of patients with severe 
or moderate periodontitis suffer from prediabetes and if two-
thirds of these benefit from nonsurgical periodontal treatment 
because progression toward hyperglycemia is retarded, then 
this basic periodontal treatment, which has no negative adverse 
side effects, must prove its utility in general clinical practice. 
To determine whether family and specialist dental practices 
can serve as potential health care providers for prediabetes 
treatment among periodontitis patients, large well-designed 
multicenter randomized clinical trials are required.
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